Filgotinib - Galapagos/Gilead Sciences
Alternative Names: Filgotinib hydrochloride; Filgotinib Maleate; G-146034; G-146034-101; GLPG-0634; GS-6034; JyselecaLatest Information Update: 22 Dec 2025
At a glance
- Originator Galapagos NV
- Developer Alfasigma; Eisai Co Ltd; Galapagos NV; Gilead Sciences
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Pyridines; Skin disorder therapies; Small molecules; Thiamorpholines; Triazoles; Urologics
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Rheumatoid arthritis; Ulcerative colitis
- Phase III Axial spondyloarthritis
- Phase I Juvenile rheumatoid arthritis
- Discontinued Ankylosing spondylitis; Crohn's disease; Cutaneous lupus erythematosus; Lupus nephritis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Sjogren's syndrome; Uveitis
Most Recent Events
- 29 Sep 2025 Phase-III clinical trials in Ulcerative colitis (In children, In adolescents, In adults) in United Kingdom, Spain, Romania, Romania, Portugal, Poland, Norway, Italy, Ireland, Greece, Germany, France, Croatia, Belgium (PO) (NCT06865417)
- 28 Jul 2025 Alfasigma plans to file MAA to EMA and MHRA for Axial spondyloarthritis
- 28 Jul 2025 Efficacy and adverse events data from a phase III OLINGUITO trial in Axial spondyloarthritis released by Alfasigma